As of 25 June 2021, the following treatments are allocated at random to hospitalized people with severe COVID-19 infection: * Baricitinib (an immunomodulatory drug used in rheumatoid arthritis) * Dimethyl fumarate (adults only, early phase assessment) * Infliximab (adults only) * High-dose dexamethasone (adults with hypoxia only) Children with PIMS-TS may also be allocated the following: * Low-dose dexamethasone (a steroid, which reduces inflammation) * Intravenous immunoglobulin * Tocilizumab (an anti-inflammatory) * Anakinra (a drug used to treat rheumatoid arthritis) The following treatments have previously been included in the trial and obtained positive results: * Low-dose dexamethasone * Tocilizumab * REGN-COV2 (a cocktail of two anti-viral monoclonal antibodies) * Baricitinib The following treatments have previously been included in the trial and were closed to new entrants after being shown to be ineffective.: * Lopinavir-Ritonavir (an HIV medication) * Hydroxychloroquine (used to treat malaria and rheumatism) * Azithromycin (an antibiotic) * Convalescent plasma (blood plasma from people who have<unk> d from COVID-19 and which may contain antibodies against the SARS-CoV-2 virus) * Aspirin (a commonly used blood thinner) * Colchicine (a drug used for gout)
RECOVERY Trial
MOMS Trial
STEPS trial
ASTEROID trial
AURORA trial
Intersalt study
Solidarity trial
PLOS Clinical Trials